We are excited to announce that Eagle IP has been named as a finalist for the Life Sciences Patent Network (LSPN) Awards USA 2025 in the following categories:   

  1. Inspiring Woman of the Year: This nomination recognizes our President and Managing Director, Ms. Jennifer Che, for her outstanding leadership, innovation, and dedication to empowering others in the industry.  
  1. International Firm of the Year: This nomination recognizes the excellence and achievements of international firms, such as Eagle IP. 

We are truly honored to be shortlisted in two different categories for the LSPN Awards USA 2025!  This award recognizes "excellence, innovation, and leadership in life sciences IP" and tries to identify individuals and organizations that are "shaping the future of pharmaceutical and biotech patent protection." This recognition is a testament to the hard work and dedication of our entire team. A heartfelt THANK YOU to our clients for your trust and support, to our incredible team for their continued pursuit of excellence, and to our partners for their collaboration. 

You can see all the finalists here. 

我們過去活動

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by ManagingIP

2025年6月13日

Eagle IP Ranked Among Top Tier Firms in IAM Patent 1000

2025年6月12日

Jennifer Che from Eagle IP to Attend BIO 2025 in Boston!

2025年6月11日

Insights from HKSTP Market Discovery - BIO Connect

2025年5月28日

HKMHDIA Medical Fair Forum

2025年5月27日

Celebrating Innovation at the Asia Summit for Global Health

2025年5月26日

Recommended Insights

New Remedy in China for Fixing "Errors" in a Patent Application: Incorporation by Reference

2024年3月21日
Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released the new […]
閱讀更多 >

Everything you need to know about Patent Term Adjustment (PTA) in China

2024年5月7日
We previously discussed patent term compensation for patent office delay (‘Patent Term Adjustment’ or ‘PTA’) when such new system was introduced in the Fourth Amendment of the Chinese Patent Law (2020), as well as in the different versions of the Draft Examination Guidelines released in 2021 and 2022. In this article, we consolidate everything you need to […]
閱讀更多 >

How to Protect a Crystal Form (Polymorph) Patent in China

2025年6月4日
Crystalline forms are critical to pharmaceutical patents, offering extended protection for improved stability, bioavailability, or manufacturability. However, securing such patents in China has grown increasingly difficult due to the China National Intellectual Property Administration (CNIPA)’s strict patentability criteria. Unlike the U.S. or Europe, where structural novelty or problem-solving utility may suffice, China demands quantifiable evidence of […]
閱讀更多 >

China Hands Down First Batch of Patent Linkage “Paragraph IV” Litigation Results

2022年6月30日
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage. Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]
閱讀更多 >
Top crossarrow-right